4P-Phar­ma rais­es €15M; On­cotel­ic Ther­a­peu­tics sells rights to can­cer as­sets

Last year
News Briefing

Ono Phar­ma­ceu­ti­cal ac­quires De­ci­phera for $2.4B af­ter biotech's Phase 3 win

Last year
Deals

FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

Last year
Pharma
FDA+

As­traZeneca, Dai­ichi Sankyo’s En­her­tu claims an­oth­er Phase 3 vic­to­ry in HER2-low breast can­cer

Last year
R&D

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

Last year
R&D

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

Last year
Startups
Deals

Bris­tol My­ers eyes ma­jor cuts; That $1B AI start­up; Phar­ma re­acts to Chi­na bill; Q1 earn­ings high­lights; and more

Last year
Weekly

CHMP rec­om­mends eight new drug ap­provals, six la­bel ex­pan­sions

Last year
Pharma
FDA+

FDA green­lights la­bel up­date to Gilead­'s Bik­tarvy to in­clude more da­ta in preg­nant peo­ple

Last year
Pharma
FDA+

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Last year
Pharma
FDA+

Ipsen match­es rare dis­ease and Tik­Tok in­flu­encers to cre­ate con­nec­tions

Last year
Pharma
Marketing

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Last year
Pharma
Cell/Gene Tx

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Last year
Pharma

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Last year
R&D
AI

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Last year
News Briefing

Cigna’s Ever­north just made a move to boost Hu­mi­ra biosim­i­lar use

Last year
Pharma
Health Tech

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Last year
Pharma
Cell/Gene Tx

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Last year
People
Peer Review

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Last year
R&D
Pharma

In rare move, Colom­bia is­sues com­pul­so­ry li­cense for HIV med­i­cine in ef­fort to ex­pand ac­cess

Last year
Pharma
FDA+

Es­teve to ac­quire Per­rigo's rare dis­ease phar­ma busi­ness for up to $295M

Last year
Deals
Pharma

FDA re­vis­es guid­ance on biosim­i­lar pro­mo­tion­al la­bels and ad­ver­tis­ing

Last year
FDA+
Marketing

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Last year
Pharma
Law

As­traZeneca on emerg­ing mar­kets, GLP-1 plans and why it’s se­lec­tive about vac­cines

Last year
Pharma
First page Previous page 165166167168169170171 Next page Last page
A service from the Financial Times